Sökning: WFRF:(Mayer Gert)
> (2009) >
Rosuvastatin and ca...
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
-
- Fellström, Bengt (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Renal Medicine
-
Jardine, Alan G (författare)
-
Schmieder, Roland E (författare)
-
visa fler...
-
Holdaas, Hallvard (författare)
-
Bannister, Kym (författare)
-
Beutler, Jaap (författare)
-
Chae, Dong-Wan (författare)
-
Chevaile, Alejandro (författare)
-
Cobbe, Stuart M (författare)
-
Grönhagen-Riska, Carola (författare)
-
De Lima, José J (författare)
-
Lins, Robert (författare)
-
Mayer, Gert (författare)
-
McMahon, Alan W (författare)
-
Parving, Hans-Henrik (författare)
-
Remuzzi, Giuseppe (författare)
-
- Samuelsson, Ola, 1952 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Sonkodi, Sandor (författare)
-
Sci, D (författare)
-
Süleymanlar, Gultekin (författare)
-
Tsakiris, Dimitrios (författare)
-
Tesar, Vladimir (författare)
-
Todorov, Vasil (författare)
-
Wiecek, Andrzej (författare)
-
Wüthrich, Rudolf P (författare)
-
Gottlow, Mattis, 1973 (författare)
-
Johnsson, Eva (författare)
-
Zannad, Faiez (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009
- 2009
- Engelska.
-
Ingår i: The New England journal of medicine. - 1533-4406 .- 0028-4793. ; 360:14, s. 1395-407
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved. METHODS: We conducted an international, multicenter, randomized, double-blind, prospective trial involving 2776 patients, 50 to 80 years of age, who were undergoing maintenance hemodialysis. We randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary end points included death from all causes and individual cardiac and vascular events. RESULTS: After 3 months, the mean reduction in low-density lipoprotein (LDL) cholesterol levels was 43% in patients receiving rosuvastatin, from a mean baseline level of 100 mg per deciliter (2.6 mmol per liter). During a median follow-up period of 3.8 years, 396 patients in the rosuvastatin group and 408 patients in the placebo group reached the primary end point (9.2 and 9.5 events per 100 patient-years, respectively; hazard ratio for the combined end point in the rosuvastatin group vs. the placebo group, 0.96; 95% confidence interval [CI], 0.84 to 1.11; P=0.59). Rosuvastatin had no effect on individual components of the primary end point. There was also no significant effect on all-cause mortality (13.5 vs. 14.0 events per 100 patient-years; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.51). CONCLUSIONS: In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- Aged
- Aged
- 80 and over
- C-Reactive Protein
- analysis
- Cardiovascular Diseases
- mortality
- prevention & control
- Cholesterol
- blood
- Double-Blind Method
- Female
- Fluorobenzenes
- adverse effects
- therapeutic use
- Follow-Up Studies
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- adverse effects
- therapeutic use
- Kaplan-Meiers Estimate
- Kidney Failure
- Chronic
- blood
- drug therapy
- mortality
- therapy
- Male
- Middle Aged
- Prospective Studies
- Pyrimidines
- adverse effects
- therapeutic use
- Renal Dialysis
- adverse effects
- Sulfonamides
- adverse effects
- therapeutic use
- Treatment Failure
- Kidney diseases
- Medicine
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Fellström, Bengt
-
Jardine, Alan G
-
Schmieder, Rolan ...
-
Holdaas, Hallvar ...
-
Bannister, Kym
-
Beutler, Jaap
-
visa fler...
-
Chae, Dong-Wan
-
Chevaile, Alejan ...
-
Cobbe, Stuart M
-
Grönhagen-Riska, ...
-
De Lima, José J
-
Lins, Robert
-
Mayer, Gert
-
McMahon, Alan W
-
Parving, Hans-He ...
-
Remuzzi, Giusepp ...
-
Samuelsson, Ola, ...
-
Sonkodi, Sandor
-
Sci, D
-
Süleymanlar, Gul ...
-
Tsakiris, Dimitr ...
-
Tesar, Vladimir
-
Todorov, Vasil
-
Wiecek, Andrzej
-
Wüthrich, Rudolf ...
-
Gottlow, Mattis, ...
-
Johnsson, Eva
-
Zannad, Faiez
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
The New England ...
- Av lärosätet
-
Göteborgs universitet
-
Uppsala universitet